GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Forward PE Ratio
中文

Trinity Biotech (Trinity Biotech) Forward PE Ratio : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Forward PE Ratio?

Trinity Biotech's Forward PE Ratio for today is 0.00.

Trinity Biotech's PE Ratio without NRI for today is 0.00.

Trinity Biotech's PE Ratio for today is 0.00.


Trinity Biotech Forward PE Ratio Historical Data

The historical data trend for Trinity Biotech's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Forward PE Ratio Chart

Trinity Biotech Annual Data
Trend 2015-12 2016-11 2023-09
Forward PE Ratio
26.74 23.26 5.25

Trinity Biotech Quarterly Data
2015-12 2016-03
Forward PE Ratio 26.74 25.91

Competitive Comparison of Trinity Biotech's Forward PE Ratio

For the Diagnostics & Research subindustry, Trinity Biotech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Forward PE Ratio falls into.



Trinity Biotech Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Trinity Biotech  (NAS:TRIB) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Trinity Biotech Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.